Trial Profile
Open-Label, Follow-up, Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated Using a Rapid Immunization Schedule (Follow-up to Study 225)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2015
Price :
$35
*
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
- 18 Jun 2013 New trial record